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ABSTRACT 
A series of new dioxidovanadium(V) complexes [VO2L
1-4
] (1-4) have been reported. The 
complexes are obtained from the reaction of the HL
1-4
 with VO(acac)2 in 1:1 molar ratio in 
different solvent medium. All the synthesized ligands and the metal complex are successfully 
characterized by elemental analysis, IR and UV-vis spectroscopy. From various studies it is 
indicated that all the complexes possess square pyramidal structure. 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
In past few years metal complexes of biologically active ligands has gain much interest in the 
field of coordination chemistry,
1-3
 it may be due to the fact that, chelation has much effect in 
biological properties of  ligands as well as metal involved. It is well reported in the literature that 
chelation is the cause and cure of many diseases including the disease like cancer. 
Vanadium being a versatile metal with variable oxidation state has explored much in 
coordination chemistry in past few decades. Synthesis, characterization, properties and 
application of vanadium complexes in diverse fields have a widespread interest. This metal act as 
active site in various enzymes such as vanadium-dependent nitrogenases, haloperoxidase,
4–10
 
which stimulated the research for functional model. Due to the discovery of Amarnita muscaria, 
which contains vanadium in the form of vanadate ion (VO
3+)
 in a nonporphyrinic O/N donor 
environment,
11-12
 interest in this field has been increased. Vanadium compounds found to show 
activity like anti-carcinogenic,
13
 anti-leishmanial
14
 etc. which, enhances its biological 
importance. Moreover, inorganic vanadyl and vanadate, as well as some vanadium (IV) and (V) 
complexes, are potent insulin mimics and as such may find use as alternatives to insulin in the 
treatment of diabetes.
15
  
    On the other hand, hydrazones, –NH–N=CRR' (R and R  = H, alkyl, aryl), are versatile ligands 
due to their applications in the field of analytical
16
 and medicinal chemistry.
17
 Hydrazone 
moieties are the most important pharmacophoric cores of several anticancer, antiinflammatory, 
antinociceptive, and antiplatelet drugs.
18 
Kiran Singh and group
19
 have reported the a series of metal complexes of Co(II), Ni(II), Cu(II) 
and Zn(II) (Figure-1) prepared from biologically active ligands. These ligands were prepared by 
the condensation of 4-amino-5-mercapto-3-methyl-s-triazole (AMMT), 4-Amino-3-ethyl-5-
mercapto-s-triazole (AEMT) with 2-acetylpyridine. Antibacterial activities of 10 complexes have 
been studied in vitro. It was observed that heterocyclic bidentate Schiff bases were associated 
with substantially higher antibacterial activities than some commercial antibiotics. 
 
(Figure-1) 
Hafez et. al
20
 have reported the synthesis of two series of 5-ethyl-2-amino-3-pyrazolyl-4-methyl 
thiophenecarboxylated and 2-thioxo-N
3
-aminothieno
2,3-d 
pyrimidines from 3,5-diethyl-2-amino-
4-methylthio-phenecarboxylate and evaluated as anti-inflammatoryanalgesic and ulcerogenic 
activities (Figure-2). Some of the compounds containing the substituted hydrazide showed more 
potent anti-inflammatory activity and analgesic activities than the than the standard drug 
(Indomethanic and aspirin) along without ulcerogenity. 
 
(Figure-2) 
Cheng et. al.
21
 have been reported the synthesized and characterized of two trinuclear complexes, 
Cu3L2(py)2 (1) and Ni3L2(py)4(2) (Figure-3),where central metal ion and two trinuclear metal 
ions in the two complexes are combined by two bridging deprotonated L
3-
 ligand forming a bent 
trinuclear structure. Antibacterial screening data indicate all compounds have stronger 
antimicrobial activities against the tested microorganisms than ligand. 
 
(Figure-3). 
Patel and coworkers
22
 have reported the superoxide dismutase (SOD) and antimicrobial 
properties of copper (II) complexes complexes of the type [Cu(L)X2)], where L = (E)-N-phenyl-
2-[phenyl (pyridine-2-yl)methylene]hydrazinecarboxamide X =Cl/Br (Figure-4). The superoxide 
dismutase activity reveals that these two complexes catalyze the fast disproportionationof 
superoxide in DMSO solution.  
 
 
 
 
 
                  
                                                                (Figure-4). 
         
 Dharmaraj et. al
23
 have reported  synthesised of bivalent, ruthenium organometallics containing 
hydrazone ligands with the composition [RuH(-CO)(PPh3)2(L
1-3
)] (Figure-5), from the reactions 
of [RuH2(CO)(PPh3)3] and benzoic acid pyridine-2-ylmethylene-hydrazide (HL1) (1) /benzoic 
acid (1-pyridin-2-yl-ethylidene)-hydrazide (HL2)(2)/benzoic acid (phenyl-pyridin-2-yl-
methylene)-hydrazide (HL3) (3) and characterised by variousphysicoechemical techniques. Here 
it is reported that substitution (H or CH3 or C6H5) at the azomethine carbon of coordinated 
hydrazones in these ruthenium has marked effect on the potential binding with DNA/BSA, free 
radical scavenging and cytotoxicity. 
 
 
                                                                 (Figure-5) 
 
N. Dharmaraj
 
and group
24
 have also reported the synthesis of bivalent transition metal hydrazone 
complexes of Ni (II)and Co(II) derived from 2-acetyl pyridine and carboxylic acid hydrazides of 
benzhydrazide or thiophene-2-carboxylic acid hydrazide (Figure-6). To explore the potential 
medicinal value of the complexes, binding interaction of all the complexes with bovine serum 
albumin (BSA) was studied at normal physiological conditions using fluorescence and UV–Vis 
spectral techniques.  
 
 
(Figure-6) 
 
Cai-feng Bi
25
 have been reported the synthesis and characterization of several  transition metal 
coordination complexes of Cu, Zn, Cd by taking 2-acetyl pyridine derivative as ligand systems. 
These compounds  are screened for anticancer activities of these three complexes on MDA-MB-
231 breast cancer cells and was found that all the three complexes can inhibit the cellular 
proliferation. In addition, the cadmium complex, can inhibit proteasomal chymotrypsin-like 
activity and also can induce apoptosis on human breast cancer. 
 
From the literature survey it is obvious that, though the chemistry of metal complex having 
bioactive heterocycles is quite developed, but that of with vanadium is less well known and are 
need to be explored. Keeping this observation in mind and in continuation of our studies on 
dioxidovanadium complexes of hydrazone Schiff base ligands, in this dissertation, I have 
reported the synthesis, full characterizations of four new tridentate ligands containing 
heterocyclic group and corresponding dioxidovanadium(V) complexes. All the synthesized 
ligands and corresponding metal complex have been characterized by several spectroscopic 
techniques. The X-ray study of one of the complex is reported and others are under process.  
2. EXPERIMENTAL 
2.1. Physical Measurements: 
Elemental analyses (C, H, N) were performed by Vario ELcube CHNS Elemental analyzer. FTIR 
spectra (4000-400 cm
-1
) as KBr discs of the samples were recorded on a Perkin Elmer spectrum 
RXI. Electronic spectra were obtained using a Perkin Elmer Lambda 35 UV/VIS 
spectrophotometer.
 
 
2.2. Chemicals and solvents: 
Chemicals were procured from companies like Aldrich, E. Merck and Fluka and used without 
further purification. HPLC grade acetonitrile, dichloromethane and chloroform were used for 
spectroscopic studies. All other solvents were A.R. grade and used as received for synthetic 
work. NH4VO3 and VOSO4 were procured from Loba Chemie. [VO(acac)2] was synthesized in 
the laboratory by following the procedure which has been described in the literature.
26
 
2.3. Work plan:  
This proposal is concerned with the design of various tridentate ligands (NNO) having pyridine 
derivatives and synthesis of the corresponding dioxidovanadium complexes by the reaction of 
tridentate ligands with various metal precursor of vanadium. The different steps of the 
methodology are given below. 
2.4. Synthesis of the Ligands: 
Schiff base ligands, (HL
1-3
) were prepared by condensation of acidhydrazides and the 
corresponding ketone of pyridine derivative in stirring ethanol medium by following a standard 
procedure.
27
 Whereas ligand HL
4
 is prepared by condensation of 2-amino benzohydrazide with 
2-benzoyl pyridine in refluxing methanol medium. The resulting white compound was filtered, 
washed with ethanol and dried over fused CaCl2. 
2.5. Synthesis of complexes [VO2L
1-3
](1-3): 
To the hot solution of ligand, HL
1-3 
in refluxing methanol medium, [VO(acac)2] in DMF was 
added the color changed instantly to greenish brown. It was cooled, filtered off and kept for 
crystallization. Slow evaporation of the filtrate over 4 days produced yellow crystalline 
compounds. The characterizations of the complexes were done systematically. Yield: ~ 60%. 
2.6 Synthesis of complex [VO2L
4
](4): 
To the hot solution of ligand, HL
4
 in methanol medium, [VO(acac)2] was added, the color 
changed instantly to orange. After reflux, it was cooled, filtered off and kept for crystallization. 
Slow evaporation of the filtrate produced orange crystals. Some crystals are of diffraction quality 
and were used directly for X-ray structure determination using single crystal X-ray 
diffractometer. Yield: 64%.  
3. RESULTS AND DISCUSSION 
The spectral (IR, UV-Vis) data of the ligand, H2L
1
 and their corresponding dioxidovanadium (V) 
complex, [VO2L
1
](1) are given in below. The infrared spectra of the complex display 
characteristics similar to a dioxidovanadium complex. The disappearance of characteristic bands 
due –NH and –C=O in the ligand spectra, and the appearance of new bands in the range 1253 
cm
–1
 in the complex indicates the enolization of these two groups forming a –N=C–O bond 
sequence. The strong and sharp peak displayed by the complexes in the range 1595 cm
-1
 is likely 
to be associated with the –C=N–N=C– moiety.28,29 The presence of two strong bands in the range 
956, 941 cm
-1 
is assigned to V=O stretching,
30 
which clearly indicates the dioxido nature of the 
complex shown in (Figure 7-8). 
 
 
Figure-7 FTIR Spectrum of (E)-N-(1-pryidin-2-yl)ethylidene)-1-naphthohydrazide (HL
1
) 
 
Figure-8 FTIR Spectrum of complex (VO2L
1
)(1) 
 
The electronic spectrum of the complex 1 was recorded in DMF. The strong absorption 
observed at the wavelength 397nm is assignable to the ligand-to-metal charge transfer transitions 
whereas the other bands in the higher energy region (286–263 nm) are likely to be due to ligand 
centred transitions.
28
 shown in (Figure 9). 
 
                                              Figure-9 UV-vis Spectrum of complex (VO2L
1
)(1) 
 
4. CONCLUSION 
Four Schiff’s base hydrazone ligands were synthesized and successfully characterized by IR and 
elemental (C, H, N) analyzer. The basic and electronic property of these ligands has been nicely 
explored in the syntheses of corresponding dioxidovanadium(V) complexes. All the four 
complexes reported here, has been fully characterized by IR and UV-visible spectroscopy. 
Biological studies are under process.  
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